ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

MaxCyte to Participate in Upcoming Investor Conferences

November 12, 2021 GMT

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences:

  • Consilium Strategic Communications 9th Annual Healthcare Conference 2021
    Panel discussion on Monday, November 15th at 8:50 a.m. Eastern Time

  • Stifel 2021 Virtual Healthcare Conference
    Fireside chat on Tuesday, November 16th at 8:00 a.m. Eastern Time

  • Stephens Annual Investment Conference
    Fireside chat on Monday, November 29th at 12:00 p.m. Eastern Time

ADVERTISEMENT

Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser 
Gilmartin Group+1 415-937-5400
David Deuchler, CFAir@maxcyte.com  
  
Nominated Adviser and Joint Corporate Broker 
Panmure Gordon+44 (0)20 7886 2500
Emma Earl / Freddy Crossley 
Corporate Broking 
Rupert Dearden 
  
UK IR Adviser+44 (0)203 709 5700
Consilium Strategic Communicationsmaxcyte@consilium-comms.com  
Mary-Jane Elliott 
Chris Welsh